The instant invention relates to a method and apparatus for complex impedance compensation, and, in another aspect, a method and apparatus for using complex impedance measurements including a phase angle to detect tissue morphology.
Many applications have been proposed for the use of a measured impedance of tissue, for example cardiac tissue, and not surprisingly a number of approaches for making such impedance measurements have also been proposed. One procedure where an impedance is measured and used is in cardiac catheter ablation.
As general background, there are a number of methods used for ablation of desired areas, including, for example, radio frequency (RF) ablation. RF ablation is accomplished by transmission of radio frequency energy to a desired target area through an electrode assembly to ablate tissue at the target site. RF ablation may generate significant heat if not controlled. It is therefore known to provide an RF ablation generator with certain feedback features, such as temperature and impedance. To provide such feedback for the physician/clinician's use during the procedure, conventional RF ablation generators are typically configured to measure and display a magnitude of a complex impedance |Z| intended to represent the impedance of the patient's tissue near and around the ablation electrode. To make the impedance measurement, conventional generators use one tip conductor (i.e., one lead through the catheter to the ablation tip electrode) and one ground conductor (i.e., one lead from a ground patch or the like back to the generator). The frequency of the source used to make the impedance measurement is generally the ablation energy source frequency, which can typically vary from 50 kHz to 500 kHz depending on the ablation generator. Such impedance measurements are commonly used to assess tissue heating and tissue-electrode contact levels. However, one shortcoming in the art is that such measurements are subject to variation due to factors unrelated to the condition of the tissue (i.e., non-physiologic changes). For example, coiling of an ablation generator cable during the procedure can increase its inductance and thus alter the impedance measurement, resulting in an inaccurate reading that is not completely indicative of the actual tissue condition. This scenario is particularly problematic where a phase angle of the complex impedance of cardiac tissue is sought, since this parameter is fairly low to begin with (<15°) for the frequencies typically used for RF ablation.
Another shortcoming is that conventional approaches for complex impedance measurements do not provide any intelligence as to tissue morphology, but rather appear to relate to tissue heating and electrode-to-tissue contact levels. An improvement to conventional approaches has been proposed which uses a phase measurement to assess the contact level for the catheter electrode. Tissue is more capacitive and resistive than myocardium due to the cell structure. Therefore, compared with blood, the measured impedance becomes more capacitive and the phase angle becomes more negative when the electrode is in contact with myocardium.
There is therefore a need to minimize or eliminate one or more of the problems set forth above.
It is desirable to be able to provide a method and apparatus for measuring a complex impedance of tissue that can incorporate compensation for changes in the equipment, namely the connecting cable, such as by cable coiling or the like. It is also desirable to provide a method and apparatus to detect tissue morphology using a complex impedance measurement, for example based on a phase angle of the tissue's complex impedance. Detecting a tissue type can be useful in various applications, including diagnosis/therapy of ventricular tachycardia (VT). For example, one of the approaches for VT ablation is to ablate on the border between the scar and normal tissue to isolate VT.
In a first aspect of the present invention, a compensation apparatus is provided directed to overcoming one or more of the problems noted above. In concept, the compensation apparatus is configured to determine a complex impedance attributable to a connecting cable. It then uses this determination to provide compensation for another complex impedance measurement within the same cable. The compensation apparatus is preferably provided for use with a catheter having an electrode and a cable. The cable is configured to allow a first electrical connection to be made between the catheter and an electrical device (e.g., an ablation generator) so as to allow the device to electrically interact with the electrode (e.g., for an ablation procedure). The first electrical connection (the “working connection”) is the one that will have the compensation (i.e., the effects of the cable removed).
The compensation apparatus includes a circuit and a compensation control. The circuit has a predetermined complex impedance when probed or excited by a pilot signal having a predetermined frequency. The known-impedance circuit is located in either the handle of the catheter or a distal end of the cable. The compensation control is configured to generate the pilot signal. The cable is arranged to allow a second electrical connection (the “control” connection) to be made between the compensation control and the circuit. The second electrical connection in the cable is the one that will be used to measure the level of undesired (non-physiologic) variations. The compensation control is configured to measure the complex impedance of the combination of the cable (i.e., over the second electrical connection) and the circuit, which has the known impedance. The compensation control is further configured to then determine a difference between the measured and known complex impedances. The difference, if any, thus represents variation due to the cable configuration, may be used for compensating on any complex impedance measurements over the first electrical connection within the same cable.
In a second aspect of the invention, a method for determining a tissue type is provided. In a preferred embodiment, the tissue under test may be one of a plurality of different tissue types, including regular myocardium, scar/ischemia and fat. The method includes the steps of providing a first electrode in contact with the tissue. Next, measuring a complex impedance, at a predetermined frequency, between the first electrode and second electrode such as a reference electrode (patch). The predetermined frequency may be between about 20 kHz and 100 kHz, which reveals the capacitive properties of the tissue, while minimizing contributions by other factors not of interest (e.g., the reactance of any blood, the reactance due to the electrode-electrolyte interface, etc.). The complex impedance includes a magnitude and a phase angle component. Finally, the method includes the step of identifying one of the tissue types based on at least one of the measured magnitude and phase angle components, preferably at least the phase angle component.
The foregoing and other aspects, features, details, utilities, and advantages of the present invention will be apparent from reading the following description and claims, and from reviewing the accompanying drawings.
The invention that will be described herein includes two main aspects. In the first aspect, an apparatus and method for complex impedance compensation is provided. The first aspect of the invention overcomes a problem described in the Background, namely, changes in the measured complex impedance that are observed but which are due to changes in the configuration of the equipment, namely the connecting, such as by cable coiling and the like. The first aspect provides the ability to measure the complex impedance with respect to the tissue more accurately, which, as understood by those in the art, will have many useful applications. In the second aspect of the invention, an apparatus and method is provided for determining a tissue type based on, preferably, a phase angle component and/or also a magnitude component of the tissue's complex impedance. The second aspect of the invention is useful in identifying tissue during certain applications, for example, identifying scar tissue in ventricular tachycardia (VT) applications or epicardial applications for locating fat and scar tissue. For VT ablation, one of the current approaches is to ablate on the border between the scar and normal tissue to isolate the scar that triggers VT. As to epicardial RF application, one of the important issues is to apply energy to regular tissue and avoid RF application on fat which does not create an efficacious lesion.
It should be understood that the two aspects of the invention are not limited to the particular illustrated embodiments. For example, the apparatus and method for each may be used with catheters/catheter systems for diagnostic, therapeutic, mapping and/or ablative procedures, to name just a few.
As further background, a complex impedance (Z) can be expressed as set forth in equation (1)
Z=R+jX (1)
Where R is a resistance component; and X is a reactance component that is based on both capacitance and inductance contributions. A complex impedance can also be expressed as set forth in equation (2):
Z=|Z|<ϕ (2)
Where |Z| is the magnitude of the complex impedance and ϕ is called the phase angle or alternatively sometimes simply the “phase.” These quantities are defined in equations (3) and (4):
|Z|=√{square root over (R2+X2)} (3)
tan ϕ=X/R (4)
As used herein, the term complex impedance is taken to include a magnitude and a phase angle. Where a magnitude of the complex impedance is intended, an absolute value of Z will be denoted, |Z|. With this background, the first and second aspects of the invention will now be set forth.
Impedance Compensation for Catheters and Cables
Referring now to the drawings wherein like reference numerals are used to identify identical components in the various views,
With continued reference to
The catheter 12 may include a cable connector or interface 18, a handle 20 and a shaft 22 having a proximal end 24 and a distal end 26 near which an ablation electrode 28 is disposed. It should be re-iterated that while one electrode 28 is shown, the catheter 12 may include a plurality of electrodes, and that in any event, the electrode 28, in other embodiments (other than RF ablation) may be used for any number of diagnostic and/or therapeutic purposes. For instance, such electrodes and therefore such catheters may be used for performing ablation procedures, cardiac mapping, electrophysiological (EP) studies, and other like procedures. Accordingly, the present invention is not limited to any one type of catheter or catheter-based system or procedure.
The general structural and functional features of catheter systems such as those generally comprising the catheter 12, the fluid source 14 and the RF ablation generator 16 are generally well known to those of skill in the art. For example, the fluid source 14 can comprise various known assembly, including fixed volume rolling pumps, variable volume syringe pumps and other pump assembly known to those skill in the art. Moreover, the fluid provided by fluid source 14 may comprise a suitable biocompatible fluid, such as saline. Subject to the modifications described below, the RF ablation generator 16 may comprise conventional apparatus, such as a commercially available unit sold under the model number IBI-1500T RF Cardiac Ablation Generator, available from Irvine Biomedical, Inc. Of course, the RF ablation generator 16 can also comprise various other known energy sources.
With continued reference to
As shown, the cable 40 is configured generally to allow the first electrical connection 48 to be made between the RF ablation source 30 and the catheter 12 (i.e., and in turn to the ablation tip electrode 28). The first electrical connection 48 is the connection for which compensation will be made. Additionally, the cable 40 is configured to allow the second electrical connection 50 to be made between the compensation control 42 and the known-impedance circuit 38. The second electrical connection 50 is the connection upon which the difference signal 46 (i.e., a compensation or cancellation factor) will be determined. While the second connection 50 is illustrated in exemplary fashion as having two wires, it should be understood that the invention is not so limited. More than two wires may be used to form the second electrical connection 50, and likewise, a single wire may be employed.
The compensation control 42 is configured to generate the above-described pilot signal at the predetermined frequency for probing or exciting the circuit 38. Specifically, the compensation control 42 is configured to measure the complex impedance of the combination of the second electrical connection 50 and the circuit 38. Since the complex impedance of the circuit 38 is known and available in advance, the compensation control 42 is further configured to determine a difference between the measured complex impedance and the predetermined (known) complex impedance of the circuit 38. Any difference, be it expressed in terms of a magnitude (e.g., ohms), a phase angle (e.g., degrees) or both, would then be deemed attributable to the configuration of the cable 40. The compensation control 42 is thus further configured to generate the difference signal 46 indicative of the difference as determined by the control 42. For example, if the measured complex impedance, when taken relative to the predetermined, known complex impedance, indicates an additional phase lag of X degrees due to cable coiling or the like adding inductance, the difference signal 46 may be generated to indicate the additional X degrees lag. The difference signal 46 is provided to the complex impedance determining circuit 32, which is configured to use the difference signal 46 in making compensatory adjustments. Specifically, the circuit 32 is configured to use the difference signal 46 to cancel or null out cable configuration-related variations in any measured complex impedance taken over the first electrical connection 48. The particulars of the difference signal may take many forms, although it should be understood that the selected form will be coordinated with the form expected by the complex impedance determining circuit 32.
The compensation control 42, in one embodiment, may be a computer-implemented apparatus operating under software control. For this purpose, a controller 52 (which may already be present in the ablation generator 16 if integrated) may be configured to execute pre-programmed instructions to perform the various functions described herein. The compensation control 42 may include various controlled hardware, such as a pilot source generator to generate the pilot signal, as well as structure suitable for measuring the resultant signal induced by the application of the pilot signal over the second electrical connection 50 to the circuit 38. These structures may comprise conventional apparatus well known to those of ordinary skill in the art. In the computer-implemented embodiment, the difference signal 46 may take the form of a compensation factor or parameter, which may be stored in a memory and available for access by the impedance determining circuit 32. Additionally, the compensation control 42 may be further configured to update the difference signal 46 on a periodic basis, so as to provide real-time complex impedance compensation.
In an alternate embodiment, the compensation control 42 may be implemented completely in hardware employing various means to measure a difference in magnitude and phase (e.g., phase detector) between the measured complex impedance (i.e., the cable plus the circuit 38) and the predetermined known complex impedance of the circuit 38.
Step 54 involves the step of providing a circuit (e.g., the circuit 38) having a known, predetermined complex impedance at a predetermined frequency of interest (see above description of the predetermined frequency). The circuit 38 may be located in the handle of a catheter, or in the distal end of a connecting cable. The criteria for locating the circuit 38 is to include as much of the cable, preferably all of the cable, in the complex impedance measurement. The method proceeds to step 56.
Step 56 involves the step of probing or exciting the circuit 38 using the pilot signal at the predetermined frequency over an electrical connection (e.g., the electrical connection 50) in the cable 40. The method proceeds to step 58.
Step 58 involves the step of measuring the combined complex impedance of the electrical connection 50 and the circuit 38. The method proceeds to step 60.
Step 60 involves the step of determining a difference between the measured complex impedance (cable plus circuit 38) and the predetermined, known complex impedance of the circuit 38. This difference may be a phase angle shift (degrees), a difference in magnitude (ohms), or both. The method then proceeds to step 62.
Step 62 involves the step of using the determined difference for compensation purposes in measurements (e.g., complex impedance measurements) conducted over other electrical connections in the same cable. For example, the complex impedance may be measured through the first electrical connection using the catheter electrode. Then, the difference may be cancelled out of such other complex impedance measurement, thereby removing the effect of the cable configuration. Through the foregoing, changes that might occur in the cable can be quantified and removed, leaving only the accurate measurement intended (e.g., the complex impedance measurement of the subject tissue).
While the first aspect for an inventive compensation scheme was described in connection with an RF ablation system, it should be understood that this aspect of the invention is not so limited, and may be employed in a variety of other configurations where a catheter and one of its electrodes is used to conduct a diagnostic or therapeutic function.
Determining Tissue Morphology Based on Phase Angle
In the second aspect of the invention, an apparatus and method is described for determining tissue morphology based on a phase angle and/or additionally a magnitude of the tissue's complex impedance. In the field of cardiac catheter ablation, “impedance” conventionally means the magnitude Z of the complex impedance.
In the context of RF ablation, which is typically conducted at around 500 kHz, a working assumption is that such procedures involve nearly purely resistive heating. However, there does exist a number of sources that contribute capacitance. At least three main sources of such capacitance include: (1) blood; (2) the subject tissue; and (3) an electrode (e.g., Pt/Ir)-electrolyte (blood or saline) interface. Additional sources of capacitance include any connecting wires as well as stray capacitance. When the ablation system impedance is measured (e.g., by using an LCR impedance meter), a phase angle (or reactance component) is registered in addition to a resistance component (e.g., Z=R+jX). The reactance due to the capacitance and inductance is typically much smaller than the resistance, and the phase angle is relatively small as well (e.g., <15°). Accordingly, for most conventional purposes, such as determining tissue heating for example, the assumption that RF ablation conducted at ˜500 kHz or similar frequencies is resistive is adequate. However, for other purposes, such as the inventive approach for detecting a tissue type, this assumption is inadequate.
Investigation has shown that the three sources of capacitances described above change differently as a function of frequency. While the reactance contributed by the blood capacitance and the electrode-electrolyte interface capacitance both decrease to zero when excited at frequencies above 20 kHz (becoming essentially resistive), this is not the case with tissue. The capacitance of tissue provides a significant reactance value into the 100 kHz frequency range and does not decrease to near zero until above 500 kHz or higher, which is believed due to cell membranes contributing capacitance.
During cardiac catheter ablation, one of a plurality of different tissue types may be encountered. In the context of the exemplary embodiment, regular myocardium, scar and fat tissue types are typical of the types of tissue that can be encountered, although it should be understood that other tissue types may be appropriate for other embodiments according to the principles disclosed herein.
It is important to understand the underlying structure of the different tissue types and how such different structures affect its respective complex impedance characteristics. First, the cell structure for regular myocardium is different from that of other types of tissue considered herein such as scar and fat tissue. The major determinants affecting complex impedance of regular myocardial tissue are the extra-cellular and intra-cellular resistance, a gap junction conductance, and the cell membrane capacitance (already mentioned above). Regular myocardium therefore presents a moderate impedance (magnitude) and a regular phase angle value (negative). Scar tissue is common for ventricular tachycardia (VT) and is considered inexcitable and acellular. This makes the scar tissue more conductive and less capacitive due to lack of cell membrane, which results in low impedance and low phase angle (negative). Both the low impedance and the low phase angle of scar tissue are different from regular myocardium. Finally, fatty tissue is considered non-conductive because of the fat content, and accordingly has even higher impedance than myocardium. Fat, however, has a lower phase value because no capacitive cell membrane is present. It should be understood that the impedance (magnitude) and phase angle values for these tissue types are relative to each other. Accordingly, no specific values are necessary.
Based on the foregoing, a correlation can be made between the phase angle, on the one hand, and the tissue type, on the other hand. More specifically, based on both impedance |Z| and the phase angle ϕ, a tissue type can be determined for tissue near a measurement electrode(s), as set forth in Table 1.
Thus, using the foregoing measurement technique, a high impedance and low phase angle indicates fatty tissue. Alternatively, low impedance and low phase angle indicates a scar. Moderate impedance value (i.e. between fat and scar) and a high phase angle value indicate normal myocardium. It is important to note that phase angle values in the aforementioned paragraphs are all negative, such that a high phase angle means more negative phase angle.
According to this aspect of the invention, use of the phase angle ϕ in distinguishing tissue types is preferred because it exhibits a different and unique response for each tissue type: regular myocardium, scar and fat. Additionally, the complex magnitude (“impedance”) |Z| may be further used as well to distinguish regular tissue from irregular tissue, or even scar from fat, based on the particular values of the impedance measurements. Normally, fat is more resistive than scar tissue and this property can be used to differentiate scar from fat.
The apparatus 100 includes an excitation signal source 110, a complex impedance measurement block 112, and a tissue type identification logic block 114 configured to determine and output a tissue type 116. The excitation signal source 110 is coupled, effectively, across the first and second electrodes 104 and 106 (or alternatively 108) and is configured to generate the excitation signal used in determining the complex impedance. More particularly, the excitation signal, when applied across the electrodes, will produce a corresponding induced signal whose characteristics will be determined by, and thus be indicative of, the properties of the tissue under test. In one embodiment, the excitation signal has a predetermined frequency preferably between about 20 kHz or greater and 1000 kHz or less, and more preferably between about 50 kHz or greater and 500 kHz or less. The excitation signal source 110 may comprise conventional apparatus for generating such a signal (e.g., may be either a constant voltage or current at the predetermined frequency).
The complex impedance measurement block 112 is coupled, effectively, across the first and second electrodes 104 and 106 (or alternatively 108) and is configured to determine a complex impedance therebetween, based on the measurement of the induced signal, in view of the applied excitation signal. The block 112 may comprise conventional apparatus for performing such measurements, in view of the selected nature and format of the applied excitation signal. The source 110 and the measurement block 112 may be integrated (e.g., like an LCR meter).
The block 114 is configured to identify one of a plurality of candidate tissue types based on at least one of the phase angle and/or magnitude of the tissue's complex impedance. The block 114 is further configured to produce an output 116 reporting the identified tissue type. The block 114 may be implemented with conventional apparatus known to those of ordinary skill in the art, and may be a computer-implemented apparatus (a computer-based controller not shown) configured to operate in accord with pre-programmed instructions and data. The block 114 may thus be preconfigured to include a data structure (data structure not shown) and/or logic reflecting the relationship(s) between tissue type, on the one hand, and the expected phase angles and/or magnitudes on the other hand, such as illustrated in Table 1 for regular myocardium, scar and fat. In a preferred embodiment, the plurality of candidate tissue types includes regular myocardium, scar and fat as particularly set forth in Table 1. Practicing this aspect of the invention in software would require no more than ordinary skill in the art, in view of this enabling disclosure describing the functions to be performed. Of course, other implementations are possible, consistent with the teachings disclosed herein.
Step 118 involves the step of providing a first electrode (e.g., first electrode 104) in adequate contact with tissue where the tissue may be one of a plurality of expected, candidate tissue types. Step 118 also involves providing a second electrode, such a reference electrode patch 106 or alternatively the second electrode 108 (as described above). The method then proceeds to step 120.
Step 120 involves the step of measuring a complex impedance between the first and second electrodes using an excitation signal having a predetermined frequency. Step 120 may include the substep of selecting a value defining what specific frequency to use, the particulars of which have been described above. Additionally, the complex impedance comprises a magnitude (“impedance”) |Z| and a phase angle ϕ. The method proceeds to step 122.
Step 122 involves the step of identifying one of the plurality of candidate tissue types based on at least one of the magnitude and/or phase angle. In the embodiment described herein involving the candidate tissue types of regular myocardium, scar and fat, the phase angle ϕ is the preferred, primary parameter. The magnitude |Z| may be employed as a secondary parameter, all as described above in detail. Step 122 may further include the substep of reporting the identified tissue type. Through the foregoing, an apparatus and method is provided for determining a tissue type, based on the phase angle and/or magnitude of the tissue's complex impedance. The apparatus and method is useful in many applications, including VT applications described above.
Although numerous embodiments of this invention have been described above with a certain degree of particularity, those skilled in the art could make numerous alterations to the disclosed embodiments without departing from the spirit or scope of this invention. All directional references (e.g., upper, lower, upward, downward, left, right, leftward, rightward, top, bottom, above, below, vertical, horizontal, clockwise, and counterclockwise) are only used for identification purposes to aid the reader's understanding of the present invention, and do not create limitations, particularly as to the position, orientation, or use of the invention. Joinder references (e.g., attached, coupled, connected, and the like) are to be construed broadly and may include intermediate members between a connection of elements and relative movement between elements. As such, joinder references do not necessarily infer that two elements are directly connected and in fixed relation to each other. It is intended that all matter contained in the above description or shown in the accompanying drawings shall be interpreted as illustrative only and not limiting. Changes in detail or structure may be made without departing from the spirit of the invention as defined in the appended claims.
This is a divisional application of U.S. application Ser. No. 11/966,320, filed 28 Dec. 2007, now pending, which is hereby incorporated by reference as though fully set forth herein.
Number | Name | Date | Kind |
---|---|---|---|
2184511 | Bagno et al. | Dec 1939 | A |
3316896 | Thomasset | May 1967 | A |
3949736 | Vrana et al. | Apr 1976 | A |
4641649 | Walinsky et al. | Feb 1987 | A |
5230349 | Langberg | Jul 1993 | A |
5257635 | Langberg | Nov 1993 | A |
5297549 | Beatty et al. | Mar 1994 | A |
5311866 | Kagan et al. | May 1994 | A |
5341807 | Nardella | Aug 1994 | A |
5366896 | Margrey | Nov 1994 | A |
5423808 | Edwards et al. | Jun 1995 | A |
5429131 | Scheinman et al. | Jul 1995 | A |
5447529 | Marchlinski et al. | Sep 1995 | A |
5462544 | Saksena et al. | Oct 1995 | A |
5546940 | Panescu et al. | Aug 1996 | A |
5562721 | Marchlinski et al. | Oct 1996 | A |
5582609 | Swanson et al. | Dec 1996 | A |
5588432 | Crowley | Dec 1996 | A |
5630034 | Oikawa et al. | May 1997 | A |
5657755 | Desai | Aug 1997 | A |
5659624 | Fazzari et al. | Aug 1997 | A |
5673704 | Marchlinski et al. | Oct 1997 | A |
5688267 | Panescu et al. | Nov 1997 | A |
5697377 | Wittkampf | Dec 1997 | A |
5702386 | Stern et al. | Dec 1997 | A |
5718241 | Ben-Haim et al. | Feb 1998 | A |
5722402 | Swanson et al. | Mar 1998 | A |
5730127 | Avitall | Mar 1998 | A |
5759159 | Masreliez | Jun 1998 | A |
5782900 | de la Rama et al. | Jul 1998 | A |
5800350 | Coppleson et al. | Sep 1998 | A |
5810742 | Pearlman | Sep 1998 | A |
5814043 | Shapeton | Sep 1998 | A |
5836943 | Miller, III | Nov 1998 | A |
5836990 | Li | Nov 1998 | A |
5837001 | Mackey | Nov 1998 | A |
5846238 | Jackson et al. | Dec 1998 | A |
5904709 | Arndt et al. | May 1999 | A |
5944022 | Nardella et al. | Aug 1999 | A |
5954665 | Ben-Haim | Sep 1999 | A |
6001093 | Swanson et al. | Dec 1999 | A |
6019757 | Scheldrup | Feb 2000 | A |
6026323 | Skladnev et al. | Feb 2000 | A |
6035341 | Nunally et al. | Mar 2000 | A |
6063078 | Wittkampf | May 2000 | A |
6129669 | Panescu et al. | Oct 2000 | A |
6171304 | Netherly et al. | Jan 2001 | B1 |
6179824 | Eggers et al. | Jan 2001 | B1 |
6206874 | Ubby et al. | Mar 2001 | B1 |
6217574 | Webster | Apr 2001 | B1 |
6217576 | Tu et al. | Apr 2001 | B1 |
6221070 | Tu et al. | Apr 2001 | B1 |
6226542 | Reisfeld | May 2001 | B1 |
6233476 | Strommer et al. | May 2001 | B1 |
6246896 | Dumoulin et al. | Jun 2001 | B1 |
6256540 | Panescu et al. | Jul 2001 | B1 |
6322558 | Taylor et al. | Nov 2001 | B1 |
6337994 | Stoianovici et al. | Jan 2002 | B1 |
6391024 | Sun et al. | May 2002 | B1 |
6423057 | He et al. | Jul 2002 | B1 |
6427089 | Knowlton | Jul 2002 | B1 |
6443894 | Sumanaweera et al. | Sep 2002 | B1 |
6445952 | Manrodt et al. | Sep 2002 | B1 |
6456864 | Swanson et al. | Sep 2002 | B1 |
6468271 | Wentzel et al. | Oct 2002 | B1 |
6471693 | Carroll et al. | Oct 2002 | B1 |
6475215 | Tanrisever | Nov 2002 | B1 |
6490474 | Willis et al. | Dec 2002 | B1 |
6498944 | Ben-Haim et al. | Dec 2002 | B1 |
6507751 | Blume et al. | Jan 2003 | B2 |
6511478 | Burnside et al. | Jan 2003 | B1 |
6546270 | Goldin et al. | Apr 2003 | B1 |
6558382 | Jahns et al. | May 2003 | B2 |
6569160 | Goldin et al. | May 2003 | B1 |
6575969 | Rittman, III et al. | Jun 2003 | B1 |
6605082 | Hareyama et al. | Aug 2003 | B2 |
6652518 | Wellman et al. | Nov 2003 | B2 |
6663622 | Foley et al. | Dec 2003 | B1 |
6676654 | Balle-Petersen et al. | Jan 2004 | B1 |
6683280 | Wofford | Jan 2004 | B1 |
6690963 | Ben-Haim et al. | Feb 2004 | B2 |
6696844 | Wong et al. | Feb 2004 | B2 |
6712074 | Edwards et al. | Mar 2004 | B2 |
6743225 | Sanchez et al. | Jun 2004 | B2 |
6755790 | Stewart et al. | Jun 2004 | B2 |
6780182 | Bowman et al. | Aug 2004 | B2 |
6788967 | Ben-Haim et al. | Sep 2004 | B2 |
6813515 | Hashimshony | Nov 2004 | B2 |
6840938 | Morley et al. | Jan 2005 | B1 |
6917834 | Koblish et al. | Jul 2005 | B2 |
6918876 | Kamiyama | Jul 2005 | B1 |
6926669 | Stewart et al. | Aug 2005 | B1 |
6936047 | Nasab et al. | Aug 2005 | B2 |
6950689 | Willis et al. | Sep 2005 | B1 |
6964867 | Downs | Nov 2005 | B2 |
6965795 | Rock | Nov 2005 | B2 |
6993384 | Bradley et al. | Jan 2006 | B2 |
7041096 | Malis et al. | May 2006 | B2 |
7106043 | Da Silva et al. | Sep 2006 | B1 |
7197354 | Sobe | Mar 2007 | B2 |
7248032 | Hular et al. | Jul 2007 | B1 |
7263395 | Chan et al. | Aug 2007 | B2 |
7263397 | Hauck et al. | Aug 2007 | B2 |
7386339 | Strommer et al. | Jun 2008 | B2 |
7497858 | Chapelon et al. | Mar 2009 | B2 |
7499745 | Littrup et al. | Mar 2009 | B2 |
7536218 | Govari et al. | May 2009 | B2 |
7565613 | Forney | Jul 2009 | B2 |
7610078 | Willis | Oct 2009 | B2 |
7633502 | Willis et al. | Dec 2009 | B2 |
7671871 | Gonsalves | Mar 2010 | B2 |
7776034 | Kampa | Aug 2010 | B2 |
7819870 | Thao et al. | Oct 2010 | B2 |
7865236 | Cory et al. | Jan 2011 | B2 |
7904174 | Hammill et al. | Mar 2011 | B2 |
7925349 | Wong | Apr 2011 | B1 |
7953495 | Sommer et al. | May 2011 | B2 |
8403925 | Miller | Mar 2013 | B2 |
20010034501 | Tom | Oct 2001 | A1 |
20010039413 | Bowe | Nov 2001 | A1 |
20010047129 | Hall et al. | Nov 2001 | A1 |
20010051774 | Littrup et al. | Dec 2001 | A1 |
20020013537 | Rock | Jan 2002 | A1 |
20020022836 | Goble et al. | Feb 2002 | A1 |
20020049375 | Strommere et al. | Apr 2002 | A1 |
20020068931 | Wong et al. | Jun 2002 | A1 |
20020072686 | Hoey et al. | Jun 2002 | A1 |
20020077627 | Johnson et al. | Jun 2002 | A1 |
20020120188 | Brock et al. | Aug 2002 | A1 |
20020123749 | Jain | Sep 2002 | A1 |
20020151887 | Stern et al. | Oct 2002 | A1 |
20020177847 | Long | Nov 2002 | A1 |
20030028183 | Sanchez et al. | Feb 2003 | A1 |
20030045871 | Jain et al. | Mar 2003 | A1 |
20030060696 | Skladnev et al. | Mar 2003 | A1 |
20030065364 | Wellman et al. | Apr 2003 | A1 |
20030093067 | Panescu et al. | May 2003 | A1 |
20030093069 | Panescu et al. | May 2003 | A1 |
20030100823 | Kipke et al. | May 2003 | A1 |
20030109871 | Johnson et al. | Jun 2003 | A1 |
20030130711 | Pearson et al. | Jul 2003 | A1 |
20030187430 | Vorisek | Oct 2003 | A1 |
20040006337 | Nasab et al. | Jan 2004 | A1 |
20040030258 | Williams et al. | Feb 2004 | A1 |
20040044292 | Yasushi et al. | Mar 2004 | A1 |
20040078036 | Keidar | Apr 2004 | A1 |
20040078058 | Holmstrom et al. | Apr 2004 | A1 |
20040082946 | Malis et al. | Apr 2004 | A1 |
20040087975 | Lucatero et al. | May 2004 | A1 |
20040097806 | Hunter et al. | May 2004 | A1 |
20040147920 | Keidar | Jul 2004 | A1 |
20040181165 | Hoey et al. | Sep 2004 | A1 |
20040243018 | Organ et al. | Dec 2004 | A1 |
20040243181 | Conrad et al. | Dec 2004 | A1 |
20040267252 | Washington et al. | Dec 2004 | A1 |
20050010263 | Schauerte | Jan 2005 | A1 |
20050054944 | Nakada et al. | Mar 2005 | A1 |
20050065507 | Hartley et al. | Mar 2005 | A1 |
20050222554 | Wallace et al. | Oct 2005 | A1 |
20060011669 | Massey | Jan 2006 | A1 |
20060015033 | Blakley et al. | Jan 2006 | A1 |
20060085049 | Cory et al. | Apr 2006 | A1 |
20060173251 | Govari et al. | Aug 2006 | A1 |
20060200049 | Leo et al. | Sep 2006 | A1 |
20060235286 | Stone et al. | Oct 2006 | A1 |
20070016006 | Shachar | Jan 2007 | A1 |
20070055142 | Webler | Mar 2007 | A1 |
20070073179 | Afonso et al. | Mar 2007 | A1 |
20070083193 | Werneth et al. | Apr 2007 | A1 |
20070100332 | Paul et al. | May 2007 | A1 |
20070106289 | O'Sullivan | May 2007 | A1 |
20070118100 | Mahesh et al. | May 2007 | A1 |
20070123764 | Thao et al. | May 2007 | A1 |
20070161915 | Desai | Jul 2007 | A1 |
20070225558 | Hauck et al. | Sep 2007 | A1 |
20070225593 | Porath et al. | Sep 2007 | A1 |
20070244479 | Beatty et al. | Oct 2007 | A1 |
20070255162 | Abboud et al. | Nov 2007 | A1 |
20080091193 | Kauphusman et al. | Apr 2008 | A1 |
20080097220 | Lieber et al. | Apr 2008 | A1 |
20080097422 | Edwards et al. | Apr 2008 | A1 |
20080132890 | Woloszko et al. | Jun 2008 | A1 |
20080183071 | Strommer et al. | Jul 2008 | A1 |
20080183189 | Teichman et al. | Jul 2008 | A1 |
20080221440 | Iddan et al. | Sep 2008 | A1 |
20080234564 | Beatty et al. | Sep 2008 | A1 |
20080234574 | Hancock | Sep 2008 | A1 |
20080249536 | Stahler et al. | Oct 2008 | A1 |
20080275465 | Paul et al. | Nov 2008 | A1 |
20080288023 | John | Nov 2008 | A1 |
20080288038 | Paul et al. | Nov 2008 | A1 |
20080300589 | Paul et al. | Dec 2008 | A1 |
20080312713 | Wilfley et al. | Dec 2008 | A1 |
20090012533 | Barbagli et al. | Jan 2009 | A1 |
20090036794 | Stubhaug et al. | Feb 2009 | A1 |
20090163904 | Miller et al. | Jun 2009 | A1 |
20090171235 | Schneider et al. | Jul 2009 | A1 |
20090171345 | Miller et al. | Jul 2009 | A1 |
20090177111 | Miller et al. | Jul 2009 | A1 |
20090247942 | Kirschenman | Oct 2009 | A1 |
20090247943 | Kirschenman et al. | Oct 2009 | A1 |
20090247944 | Kirschenman et al. | Oct 2009 | A1 |
20090247993 | Kirschenman et al. | Oct 2009 | A1 |
20090248042 | Kirschenman | Oct 2009 | A1 |
20090275827 | Aiken et al. | Nov 2009 | A1 |
20090276002 | Sommer et al. | Nov 2009 | A1 |
20090306655 | Stangenes et al. | Dec 2009 | A1 |
20100069921 | Miller et al. | Mar 2010 | A1 |
20100168550 | Byrd et al. | Jul 2010 | A1 |
20100168735 | Deno et al. | Jul 2010 | A1 |
20100191089 | Stebler et al. | Jul 2010 | A1 |
20100256558 | Olson et al. | Oct 2010 | A1 |
20100274239 | Paul et al. | Oct 2010 | A1 |
20100298823 | Cao et al. | Nov 2010 | A1 |
20110015569 | Kirschenman et al. | Jan 2011 | A1 |
20110118727 | Fish et al. | May 2011 | A1 |
20110313311 | Gaw | Dec 2011 | A1 |
20110313417 | de la Rama et al. | Dec 2011 | A1 |
20120158011 | Sandhu et al. | Jun 2012 | A1 |
Number | Date | Country |
---|---|---|
1472976 | Nov 2004 | EP |
1586281 | Apr 2009 | EP |
3585491 | Nov 2004 | JP |
2005-279256 | Oct 2005 | JP |
1998046149 | Oct 1998 | WO |
2000078239 | Dec 2000 | WO |
2007067628 | Jun 2007 | WO |
WO-2007067941 | Jun 2007 | WO |
WO-2009065140 | May 2009 | WO |
2009085457 | Jul 2009 | WO |
WO-2009085457 | Jul 2009 | WO |
2009120982 | Oct 2009 | WO |
2011123669 | Oct 2011 | WO |
Entry |
---|
Avetall, Boaz et al., “The Effects of Electrode-Tissue Contact on Radiofrequency Lesion Generation”, PACE, vol. 20 Dec. 1997 , 2899-2910 |
Chakraborty, D. P. , “ROC curves predicted by a model of visual search”, Institute of Pysics Publishing, Phys. Med. Biol. 51 2006 , 3463-3482. |
Cho, Sungbo et al., “Design of electrode array for impedance measurement of lesions in arteries”, Physiol. Mease. 26 S19-S26 doi: 10.088/0967-3334/26/2/002 2005. |
Dumas, John H. et al., “Myocardial electrical impedance as a predictor of the quality of RF-induced linear lesions”, Physiological Measurement, vol. 29 2008 , Abstract only. |
Fenici, R. R. et al., “Biomagnetically localizable multipurpose catheter and method for MCG guided intracardiac electrophysiology, biopsy and ablation of cardiac arrhythmias”, International Journal of Cardiac Imaging 7 1991, 207-215. |
Gales, Rosemary et al., “Use of bioelectrical impedance analysis to assess body composition of seals”, Marine Mammal Science, vol. 10, Issue 1, Abstract Aug. 26, 2006. |
Gao, Xin et al., “Computer-Assisted Quantative Evaluation of Therapeutic Responses for Lymphoma Using Serial PET/CT Imaging”, NIH Public Access, Acad Radiol. 17(4) Apr. 2010, 1-21. |
He, Ding S. et al., “Assessment of Myocardial Lesion Size during In Vitro Radio Frequency Catheter Ablation”, IEEE Transactions on Biomedical Engineering, vol. 50, No. 6 Jun. 2003 , 768-776. |
Himel, Herman D. , “Development of a metric to assess completeness of lesions produced by radiofrequency albation in the heart”, Dept. of Biomedical Engineering, University of NC, Chapel Hill 2006 , i-xvii; 1-138. |
Holmes, Douglas et al., “Tissue Sensing Technology Enhances Lesion Formation During Irrigated Catheter Albation”, HRS 2008 , Abstract only. |
Masse, Stephane et al., “A Three-dimensional display for cardiac activation mapping”, Pace, vol. 14 Apr. 1991. |
Salazar, Y et al., “Transmural versus nontransmural in situ electrical impedance spectrum for healthy, ischemic, and healed myocardium”, IEEE Xplore, Abstract 2009. |
Zheng, Xiangsheng et al., “Electrode Impedance: An Indicator of Electrode-Tissue Contact and Lesion Dimensions During Linear Ablation”, Journal of Electrophysiology 4 2000, 645-654. |
PCT/US2006/061714 International Search Report and Written Opinion dated Sep. 22, 2008. |
PCT/US2008/084194 International Search Report dated Feb. 5, 2009. |
PCT/US2011/047235 International Search Report and Written Opinion dated Dec. 14, 2011. |
Supplemental European Search Report for EP Application No. 11842330.0, dated Jan. 20, 2014. 9 pages. |
Thomas, Stuart P., et al., Comparison of Epicardial and Endocardial Linear Ablation Using Handheld Probes, The Annals of Thoracic Surgery, vol. 75, Issue 2. pp. 543-548, Feb. 2003. |
International Search Report for PCT Application No. PCT/US2006/046565, dated May 2, 2007. 1 page. |
International Search Report and Written Opinion for PCT Application No. PCT/US2006/061716, dated Oct. 4, 2007. 7 pages. |
International Search Report and Written Opinion for PCT Application No. PCT/US2006/061712, dated Oct. 29, 2007. 7 pages. |
International Search Report and Written Opinion for PCT Application No. PCT/US2006/061710, dated Feb. 15, 2008. 10 pages. |
International Search Report and Written Opinion for PCT Application No. PCT/US2006/061711, dated Oct. 5, 2007. 8 pages. |
International Search Report and Written Opinion for PCT Application No. PCT/US2006/061713, dated Oct. 3, 2007. 1 page. |
International Search Report and Written Opinion for PCT Application No. PCT/US2006/061717, dated Oct. 4, 2007, 9 pages. |
Supplementary European Search Report for EP Application No. 06839102.8, dated Nov. 16, 2009. 7 pages. |
Supplementary European Search Report for EP Application No. 06848530,9, dated Nov. 17, 2009. 7 pages. |
Supplementary European Search Report for EP Application No. 06840133.0, dated Nov. 16, 2009. 8 pages. |
International Search Report and Written Opinion for PCT Application No. PCT/US2010/034412, dated Jun. 29, 2010. 1 page. |
Supplementary European Search Report for EP Application No. 10775417.8, dated Oct. 25, 2013. 5 pages. |
International Search Report and Written Opinion for PCT Application No. PCT/US2008/084200, dated Jan. 22, 2009. 1 page. |
International Search Report and Written Opinion for PCT Application No. PCT/US2010/034414, dated Sep. 1, 2010. 13 pages. |
Supplementary European Search Report for EP Application No. 06839102.8, dated Nov. 16, 2009. 6 pages. |
Supplementary European Search Report for EP Application No. 06848530.9, dated Nov. 17, 2009. 6 pages. |
Number | Date | Country | |
---|---|---|---|
20130023784 A1 | Jan 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11966320 | Dec 2007 | US |
Child | 13584368 | US |